Investment Rankings

Overview

This page ranks therapeutic investment opportunities in neurodegenerative disease research by various criteria including market opportunity, pipeline strength, clinical trial activity, and mechanistic novelty. These rankings help identify the most promising investment areas in neurodegeneration therapeutics.

Rankings by Pipeline Activity

Rank	Area	Active Programs	Phase 3 Programs	Investment Trend
1	Alzheimer’s Disease	180+	15	High
2	Parkinson’s Disease	120+	10	High
3	ALS	100+	7	Moderate-High
4	Huntington’s Disease	60+	4	Moderate
5	Frontotemporal Dementia	40+	3	Moderate
6	Multiple System Atrophy	25+	2	Moderate
7	Progressive Supranuclear Palsy	20+	1	Moderate
8	Corticobasal Degeneration	15+	1	Low-Moderate

Rankings by Market Opportunity

Rank	Indication	Estimated Market Size	Growth Rate
1	Alzheimer’s Disease	$30B+	15-20%/year
2	Parkinson’s Disease	$18B+	12-15%/year
3	ALS	$4B+	12-15%/year
4	Huntington’s Disease	$2.5B+	8-10%/year
5	FTD	$2B+	12-15%/year

Rankings by Mechanistic Innovation

Areas with novel mechanisms showing promising early data:

Rank	Mechanism	Development Stage	Promise Level
1	Alpha-synuclein targeting	Phase 2-3	Very High
2	Tau immunotherapy	Phase 2-3	Very High
3	Gene therapy/AAV	Phase 1-2	High
4	Protein clearance (autophagy)	Phase 1-2	High
5	Neuroprotective small molecules	Phase 1-2	Moderate-High

Rankings by Investment Activity

Therapeutic modalities attracting capital:

Rank	Modality	2024-2026 Investment	Deal Count
1	Monoclonal antibodies	$7B+	100+
2	Small molecules	$4B+	150+
3	Gene therapy	$3B+	60+
4	Cell therapy	$1.5B+	35+
5	RNA therapeutics	$800M+	25+

Key Investment Themes

Amyloid and Tau Immunotherapy

The Alzheimer’s disease pipeline is dominated by amyloid-beta and tau-targeting immunotherapies, with lecanemab and donanemab showing unprecedented Phase 3 efficacy[@lecanemab2023]. This has validating the amyloid cascade hypothesis and driving continued investment in similar approaches.

Alpha-synucleinopathies

Parkinson’s disease and related synucleinopathies represent a major unmet need with active development across multiple mechanisms[@alphasynuclein2019]:

• Immunotherapies targeting alpha-synuclein aggregation
• Small molecules inhibiting alpha-synuclein fibrillation
• Gene therapy approaches for neuroprotection

Genetic Forms

Monogenic forms of neurodegenerative diseases (APP/PSEN mutations in AD, LRRK2/GBA in PD, SOD1/C9orf72 in ALS) offer validated targets and have attracted significant investment in precision medicine approaches[@genetic2019].

Emerging Modalities

• Gene therapy: AAV-delivered genes for neuroprotection
• RNA therapeutics: ASOs and siRNA targeting disease genes
• Cell therapy: Stem cell-derived neurons and supporting cells

See Also

• Alzheimer’s Disease
• Parkinson’s Disease

External Links

• PubMed
• KEGG Pathways

References

1. van Dyck CH, et al, Lecanemab in Early Alzheimer’s Disease (2023)
2. Spillantini MG, Goedert M, Alpha-synuclein in Parkinson’s disease (2019)
3. Singleton A, et al, Genetic forms of neurodegenerative disease (2019)